What the FDA labels say about taking them together
Clarithromycin and rivaroxaban
Rivaroxaban's FDA label of September 10, 2026 names clarithromycin in its drug interactions section; the clarithromycin label PlainMeds reads does not name rivaroxaban. The rivaroxaban label: “Although clarithromycin is a combined P-gp and strong CYP3A inhibitor, pharmacokinetic data suggests that no precautions are necessary with concomitant administration with XARELTO as the change in exposure is unlikely …”
Check it at the source: the clarithromycin FDA label on DailyMed (effective April 9, 2026, Solaris Pharma Corporation); the rivaroxaban FDA label on DailyMed (effective September 10, 2026, Janssen Pharmaceuticals, Inc.).
What does the clarithromycin label say about rivaroxaban?
Clarithromycin's label (effective April 9, 2026) does not name rivaroxaban in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Clarithromycin), Solaris Pharma Corporation, effective April 9, 2026 (SPL set 4d42821d-ce7a-7d64-e063-6294a90a0875), via openFDA; the full label on DailyMed
What does the rivaroxaban label say about clarithromycin?
Rivaroxaban label, drug interactionsAlthough clarithromycin is a combined P-gp and strong CYP3A inhibitor, pharmacokinetic data suggests that no precautions are necessary with concomitant administration with XARELTO as the change in exposure is unlikely to affect the bleeding risk [see Clinical Pharmacology (12.3) ].
Source: FDA drug label (Xarelto), Janssen Pharmaceuticals, Inc., effective September 10, 2026 (SPL set 10db92f9-2300-4a80-836b-673e1ae91610), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Clarithromycin | Rivaroxaban | |
|---|---|---|
| Labeled for | Bacterial infections, Acid reflux and ulcers | Atrial fibrillation, Heart attack and coronary artery disease, Blood clots (DVT and PE), Stroke prevention |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.466 per tablet 500 mg tablet | $0.650 per tablet 2.5 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once